■人表皮生长因子受体2(HER2)阳性乳腺癌由于HER2基因过表达/扩增而与较高的转移风险和较差的总生存期(OS)相关。尽管抗HER2靶向治疗在HER2阳性晚期乳腺癌（ABC）患者中显示出生存益处，长期治疗往往会导致耐药性，使进一步的治疗选择复杂化。RC48，一种抗体-药物偶联物（ADC），结合了抗体靶向的好处和小分子药物的细胞毒性作用。
■我们介绍了一例HER2阳性ABC的女性患者，该患者在多线抗HER2靶向治疗后出现耐药性和疾病进展。在这种情况下，RC48在对HER2靶向治疗有抗性的ABC患者中表现出抗肿瘤活性。在使用120mgRC48的八个治疗周期后,肿瘤大小减小并稳定。
■本病例报告强调了RC48作为HER2靶向治疗耐药患者的潜在临床价值。
UNASSIGNED: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with a higher risk of metastasis and poorer overall survival (OS) due to HER2 gene overexpression/amplification. Although anti-HER2 targeted therapy has shown survival benefits in HER2-positive advanced breast cancer (ABC) patients, long-term treatment often leads to drug resistance, complicating further treatment options. RC48, an antibody-drug conjugate (ADC), combines the benefits of antibody targeting with the cytotoxic effects of a small molecule drug.
UNASSIGNED: We present a
case involving a female patient with HER2-positive ABC who developed drug resistance and disease progression following multi-line anti-HER2 targeted therapy. In this instance, RC48 exhibited anti-tumor activity in an ABC patient resistant to HER2-targeted therapy. After eight treatment cycles with 120 mg of RC48, the tumor size decreased and stabilized.
UNASSIGNED: This
case report underscores the potential clinical value of RC48 as a promising treatment alternative for patients resistant to HER2 targeted therapies.
PDF(Pubmed)